Bristol-Myers Squibb near settlement in Vanlev suit

Share this article:
Bristol-Myers Squibb (BMS) is close to settling a shareholder lawsuit over its failed experimental blood-pressure drug Vanlev for more than $150 million, The Wall Street Journal reported today. The settlement, which could be announced as early as this week, pertains to a suit that alleges Bristol-Myers Squibb hailed Vanlev as a potential blockbuster even as a dangerous side effect surfaced. The agreement could bring to nearly $1 billion the amount of money BMS has agreed to return to shareholders in the past two years. Vanlev was designed to treat high blood pressure and in the late 1990s was widely seen as the product that would restore BMS’ slumping drug portfolio. Some analysts predicted Vanlev could reach sales of as much as $4 billion a year. However, Vanlev never made it to market, with news of its trouble leading to sharp declines in BMS stock.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.